Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Okta, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Okta, Inc. trades at $208.75 (market cap $39.60B). The key difference: Okta, Inc. is far larger — about 13.8× Dyne Therapeutics Inc. Common Stock's market cap, and Okta, Inc. is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Okta, Inc. for 44 Days on average.
| DYN | OKTA | |
|---|---|---|
Market Cap | $2.86B | $39.60B |
Volume | 3,341,579 | 2,315,203 |
Sector | Health | Technology |
52-Week High | $26.78 | $232.13 |
52-Week Low | $14.60 | $62.93 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $2.18B | $37.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
OKTA trades at $211.92, down 6.68% today, but maintains strong analyst support with 74% buy ratings and a consensus price target of $201.76. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 EPS expected at $0.93. Revenue growth remains robust, climbing from $1.3B in 2022 to $2.6B in 2025, while achieving positive net income of $28M after years of losses. Technical indicators show a bullish trend with key support at $215.
OKTA presents a compelling growth story with improving profitability and strong positioning in identity management. The stock faces valuation concerns with a P/E of 136, but AI security initiatives and consistent earnings beats provide catalysts. Key risks include high valuation multiples and competitive pressures in cybersecurity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
